Ritlecitinib

Ritlecitinib
Clinical data
Trade namesLitfulo
Other namesPF-06651600
AHFS/Drugs.comMonograph
MedlinePlusa624015
License data
Pregnancy
category
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
  • 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
Chemical and physical data
FormulaC15H19N5O
Molar mass285.351 g·mol−1
3D model (JSmol)
  • C[C@H]1CC[C@H](CN1C(=O)C=C)NC2=C3C=CNC3=NC=N2
  • InChI=1S/C15H19N5O/c1-3-13(21)20-8-11(5-4-10(20)2)19-15-12-6-7-16-14(12)17-9-18-15/h3,6-7,9-11H,1,4-5,8H2,2H3,(H2,16,17,18,19)/t10-,11+/m0/s1
  • Key:CBRJPFGIXUFMTM-WDEREUQCSA-N
  • Key:YOZLVAFWYLSRRN-VZXYPILPSA-N

Ritlecitinib, sold under the brand name Litfulo, is a medication used for the treatment of severe alopecia areata (hair loss).[6] Ritlecitinib is a kinase inhibitor which inhibits Janus kinase 3 and tyrosine kinase.[6][9][10]

The most common side effects include headache, diarrhea, acne, rashes, eczema, fever, mouth ulcers, dizziness, shingles rash, and abnormal findings in some laboratory test results.[11]

Ritlecitinib was approved for medical use in the United States in June 2023,[6][11][12] in the European Union in September 2023,[7] and in Canada in November 2023.[4]

  1. ^ a b "Litfulo (ritlecitinib)". Therapeutic Goods Administration (TGA). 30 July 2024. Retrieved 12 October 2024.
  2. ^ https://www.tga.gov.au/resources/prescription-medicines-registrations/litfulo-pfizer-australia-pty-ltd
  3. ^ "Litfulo Product information". Health Canada. 13 February 2024. Retrieved 3 March 2024.
  4. ^ a b "Summary Basis of Decision for Litfulo". Health Canada. 18 July 2024. Retrieved 28 August 2024.
  5. ^ "Regulatory Decision Summary for Litfulo". Health Canada. 29 November 2023. Retrieved 2 April 2024.
  6. ^ a b c d "Litfulo- ritlecitinib capsule". DailyMed. U.S. National Library of Medicine. 23 June 2023. Archived from the original on 29 August 2023. Retrieved 28 August 2023.
  7. ^ a b "Litfulo EPAR". European Medicines Agency. 18 September 2023. Archived from the original on 19 September 2023. Retrieved 20 September 2023.
  8. ^ "Litfulo Product information". Union Register of medicinal products. 18 September 2023. Archived from the original on 1 October 2023. Retrieved 1 October 2023.
  9. ^ "Ritlecitinib". Inxight Drugs. Archived from the original on 25 June 2023. Retrieved 24 June 2023.
  10. ^ Ramírez-Marín HA, Tosti A (February 2022). "Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata". Drug Design, Development and Therapy. 16: 363–374. doi:10.2147/DDDT.S334727. PMC 8860347. PMID 35210753.
  11. ^ a b "Drug Trials Snapshots: Litfulo". U.S. Food and Drug Administration. 23 June 2023. Retrieved 29 April 2024. Public Domain This article incorporates text from this source, which is in the public domain.
  12. ^ "FDA Approves Pfizer's Litfulo (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata" (Press release). Pfizer. 23 June 2023. Archived from the original on 25 June 2023. Retrieved 24 June 2023 – via Business Wire.